Important Class Action Lawsuit Against PROCEPT BioRobotics Corp Raises Concerns for Investors Worldwide

Investor Alert: Class Action Lawsuit Filed Against PROCEPT BioRobotics Corporation

In an alarming turn of events for investors, Pomerantz LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation, better known as Procept. This lawsuit comes in light of significant losses suffered by investors who acquired Procept securities during a specified class period. Affected parties are encouraged to reach out to the firm for further guidance and potential restitution.

Background on the Lawsuit

The central issue lies in allegations that Procept and certain executives engaged in actions deemed as securities fraud and other unethical business practices. Investors who made their purchases between specific dates have until September 22, 2026, to seek appointment as Lead Plaintiff in the lawsuit. Interested individuals should provide their details, including mailing address and contact numbers, to facilitate communication.

The investment community was shocked when Procept's financial disclosures revealed disappointing sales figures and lowered forecasts that didn’t meet Wall Street expectations. This triggered concerns about the company's operational integrity, further fueling the legal action.

Financial Discrepancies and Market Reactions

Procept's troubles began to unfold clearly after the company released its earnings report for the second fiscal quarter of 2025. Reflecting disappointing performance, it reported sales of approximately 12,750 handpieces—far below market expectations. This inadequacy was further emphasized when CFO Kevin Waters announced that anticipated shipments for the following quarter were set at around 13,350 units, significantly under the consensus estimate of over 13,840 units.

As if to amplify investor fears, it was revealed that any efforts to improve these dismal figures would require a substantial annual growth rate of about 25% in handpiece sales by the upcoming fourth quarter. This unfortunate communication was compounded by the elimination of the Chief Commercial Officer position, which Procept claimed would strengthen their commercial execution, thus raising questions regarding the stability of the company's management and operational direction.

As a result of the increasingly negative outlook, Procept's stock price plummeted by almost 16% over just two trading days, raising urgent alarms for shareholders.

Continued Decline and Stock Price Impact

Further developments were announced on November 4, 2025, when Procept disclosed its third fiscal quarter earnings. The report indicated that sales slightly declined to 13,225 handpieces, again missing previously established sales guidance. Compounding this, the company acknowledged they would reduce annual sales forecasts from 53,000 units to 52,000 units. This admission reiterated earlier concerns, as indicated by the CFO, who noted entrenched difficulties in inventory management with customers now carrying excess stock.

As a direct result of this announcement, Procept's stock took another hit, losing over 10% in value in just two days. It was evident that investor confidence was rapidly eroding, further red flags concerning Procept’s ability to manage its operations effectively.

The situation worsened on February 25, 2026, when Procept revealed that handpiece sales had been significantly declining, with numbers dropping from 13,225 units in the previous quarter to just 9,400 units, reflecting a staggering nearly 30% sequential loss. With such dire figures on the table, Procept’s stock took a further plunge, decreasing more than 18% over a brief two-day trading crisis.

Conclusion and Moving Forward

Pomerantz LLP, a recognized leader in corporate and securities litigation, continues to advocate for investors affected by such significant financial misconduct. With roots tracing back over 85 years, the firm has a storied legacy of fighting for the rights of those who have suffered in the wake of securities fraud and corporate mismanagement. For affected investors, the opportunity for redress is now—take the time to consider joining this class action for potential restitution.

If you have been a victim of Procept’s recent operational mismanagement affecting your investment, do not hesitate to contact Pomerantz LLP for more details on how to proceed. Stand up for your rights as an investor and join others who are taking action against corporate wrongdoings.

For more information, visit Pomerantz Law Firm or contact Danielle Peyton at 646-581-9980.